Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice

Frontiers in Molecular Neuroscience

Volumn 8, Issue JULY, 2015, Pages

  Tanguy, Yannick ^a   Biferi, Maria G ^a   Besse, Aurore ^a   Astord, Stephanie ^a   Cohen Tannoudji, Mathilde ^a   Marais, Thibaut ^a   Barkats, Martine ^a  

^a Sorbonne Université   (France)

Author keywords

AAV9; AAVrh10; Adeno associated virus; Central nervous system; Gene therapy; Motor neuron; Peripheral nervous system; SMA

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR 9; ADENO ASSOCIATED VIRUS VECTOR RH10; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENETIC TRANSDUCTION; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOTONEURON; MOUSE; NEWBORN; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHWANN CELL; SCIATIC NERVE; SPINAL CORD DORSAL HORN; VIRAL GENE THERAPY; WESTERN BLOTTING;

EID: 84941001095     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2015.00036     Document Type: Article

References (47)

1. Ahmed, S. S., Li, H., Cao, C., Sikoglu, E. M., Denninger, A. R., Su, Q., et al. (2013). A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in canavan mice. Mol. Ther. 21, 2136-2147. doi: 10.1038/mt.2013.138
2. Barkats, M. (2007). Widespread Gene Delivery to Motor Neurons using Peripheral Injection of AAV Vectors. PCT/EP2008/063297 GENETHON/CNRS.
3. Benkhelifa-Ziyyat, S., Besse, A., Roda, M., Duqué, S., Astord, S., Carcenac, R., et al. (2013). Intramuscular AAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol. Ther. 21, 282-290. doi: 10.1038/mt.2012.261
4. Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., et al. (2011). Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19, 1971-1980. doi: 10.1038/mt.2011.157
5. Bucher, T., Dubreil, L., Colle, M. A., Maquigneau, M., Deniaud, J., Ledevin, M., et al. (2014). Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther. 21, 522-528. doi: 10.1038/gt.2014.16
6. Cearley, C. N., and Wolfe, J. H. (2006). Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.Mol. Ther. 13, 528-537. doi: 10.1016/j.ymthe.2005.11.015
7. Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., et al. (2009). Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73, 1662-1669. doi: 10.1212/WNL.0b013e3181c29356
8. Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., et al. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U.S.A. 97, 3428-3432. doi: 10.1073/pnas.97.7.3428
9. Davson, H., and Segal, M. B. (1996). "Morphological aspects of the barriers," inPhysiology of the CSF and Blood-brain Barrier (Boca Raton, FL: CRC Press), 93-192.
10. Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., et al. (2011). Intravenous AAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681-693. doi: 10.1093/hmg/ddq514
11. Duqué, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A. M., et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187-1196. doi: 10.1038/mt.2009.71
12. Falangola, M. F., Hanly, A., Galvao-Castro, B., and Petito, C. K. (1995). HIV infection of human choroid plexus: a possible mechanism of viral entry into the CNS. J. Neuropathol. Exp. Neurol. 54, 497-503. doi: 10.1097/00005072-199507000-00003
13. Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., and Kaspar, B. K. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65. doi: 10.1038/nbt.1515
14. Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274. doi: 10.1038/nbt.1610
15. Fu, H., Dirosario, J., Killedar, S., Zaraspe, K., and McCarty, D. M. (2011). Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 19, 1025-1033. doi: 10.1038/mt.2011.34
16. Fyfe, J. C., Menotti-Raymond, M., David, V. A., Brichta, L., Schäffer, A. A., Agarwala, R., et al. (2006). An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival.Genome Res. 16, 1084-1090. doi: 10.1101/gr.5268806
17. Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., et al. (2003). Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A. 100, 6081-6086. doi: 10.1073/pnas.0937739100
18. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J. M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859. doi: 10.1073/pnas.182412299
19. Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., and Samulski, R. J. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058-1069. doi: 10.1038/mt.2011.72
20. Grieger, J. C., and Samulski, R. J. (2012). Adeno-associated virus vectorology, manufacturing, and clinical applications. Meth. Enzymol. 507, 229-254. doi: 10.1016/B978-0-12-386509-0.00012-0
21. Harding, B. N., Kariya, S., Monani, U. R., Chung, W. K., Benton, M., Yum, S. W., et al. (2015). Spectrum of neuropathophysiology in spinal muscular atrophy type I. J. Neuropathol. Exp. Neurol. 74, 15-24. doi: 10.1097/NEN.0000000000000144
22. Hordeaux, J., Dubreil, L., Deniaud, J., Iacobelli, F., Moreau, S., Ledevin, M., et al. (2015). Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats. Gene Ther. 22, 316-324. doi: 10.1038/gt.2014.121
23. Hu, C., Busuttil, R. W., and Lipshutz, G. S. (2010). RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J. Gene Med. 12, 766-778. doi: 10.1002/jgm.1496
24. Johnson, A. K., and Gross, P. M. (1993). Sensory circumventricular organs and brain homeostatic pathways. FASEB J. 7, 678-686.
25. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369, 2097-2105. doi: 10.1016/S0140-6736(07)60982-9
26. Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., and Henning, P. P. (2008). AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol. Ther. 16, 89-96. doi: 10.1038/sj.mt.6300331
27. Le, T. T., Pham, L. T., Butchbach, M. E., Zhang, H. L., Monani, U. R., Coovert, D. D., et al. (2005). SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845-857. doi: 10.1093/hmg/ddi078
28. LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., et al. (2011). AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10, 309-319. doi: 10.1016/S1474-4422(11)70039-4
29. Mandel, R. J., and Burger, C. (2004). Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther. 6, 482-490.
30. Marks, W. J. Jr., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7, 400-408. doi: 10.1016/S1474-4422(08)70065-6
31. Mattar, C. N., Waddington, S. N., Biswas, A., Johana, N., Ng, X. W., Fisk, A. S., et al. (2013). Systemic delivery of AAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther. 20, 69-83. doi: 10.1038/gt.2011.216
32. McCown, T. J., Xiao, X., Li, J., Breese, G. R., and Samulski, R. J. (1996). Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 25, 99-107. doi: 10.1016/0006-8993(95)01488-8
33. Miyake, N., Miyake, K., Yamamoto, M., Hirai, Y., and Shimada, T. (2011). Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res. 1389, 19-26. doi: 10.1016/j.brainres.2011.03.014
34. Mori, S., Wang, L., Takeuchi, T., and Kanda, T. (2004). Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.Virology. 330, 375-383. doi: 10.1016/j.virol.2004.10.012
35. Pereira, C. F., and Nottet, H. S. L. M. (2000). The blood-brain barrier in HIV-associated dementia. Science 3, 1-8
36. Piras, B. A., O'Connor, D. M., and French, B. A. (2013). Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver. PLoS ONE 8:e75894. doi: 10.1371/journal.pone.0075894
37. Rafi, M. A., Rao, H. Z., Luzi, P., Curtis, M. T., and Wenger, D. A. (2012). Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol. Ther. 20, 2031-2042. doi: 10.1038/mt.2012.153
38. Ruzo, A., Marcó, S., García, M., Villacampa, P., Ribera, A., Ayuso, E., et al. (2012). Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.Hum. Gene Ther. 23, 1237-1246. doi: 10.1089/hum.2012.029
39. Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., et al. (2007). Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 15, 481-491. doi: 10.1038/sj.mt.6300049
40. Tardieu, M., Zérah, M., Husson, B., De Bournonville, S., Deiva, K., Adamsbaum, C., et al. (2014). Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 5, 506-516 doi: 10.1089/hum.2013.238
41. Thwaite, R., Pagès, G., Chillón, M., and Bosch, A. (2015). AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy.Gene Ther. 22, 196-201. doi: 10.1038/gt.2014.103
42. Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., et al. (2010). Systemic delivery of AAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35-42. doi: 10.1126/scitranslmed.3000830
43. Weinberg, M. S., Samulski, R. J., and McCown, T. J. (2013). Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 69, 82-88. doi: 10.1016/j.neuropharm.2012.03.004
44. White, E., Bienemann, A., Megraw, L., Bunnun, C., and Gill, S. (2011). Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther. 18, 358-369. doi: 10.1038/cgt.2011.2
45. Wu, P., Phillips, M. I., Bui, J., and Terwilliger, E. F. (1998). Adeno-associated virus vector-mediated transgene integration into neurons and other nondividing cell targets.J. Virol. 72, 5919-5926.
46. Yamashita, T., Chai, H. L., Teramoto, S., Tsuji, S., Shimazaki, K., Muramatsu, S., et al. (2013). Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol. Med. 5, 1710-1719. doi: 10.1002/emmm.201302935
47. Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., et al. (2011). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440-1448. doi: 10.1038/mt.2011.98